Aerie Pharmaceuticals Inc (NASDAQ:AERI) Expected to Announce Quarterly Sales of $16.29 Million

Brokerages forecast that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will announce sales of $16.29 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Aerie Pharmaceuticals’ earnings. The highest sales estimate is $18.80 million and the lowest is $14.00 million. Aerie Pharmaceuticals posted sales of $2.42 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 573.1%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Aerie Pharmaceuticals will report full-year sales of $103.70 million for the current financial year, with estimates ranging from $95.59 million to $116.00 million. For the next year, analysts expect that the firm will report sales of $249.82 million, with estimates ranging from $214.80 million to $270.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.13. The firm had revenue of $10.85 million during the quarter, compared to analysts’ expectations of $12.66 million. Aerie Pharmaceuticals had a negative return on equity of 93.96% and a negative net margin of 684.56%.

AERI has been the topic of several recent analyst reports. Zacks Investment Research raised Booz Allen Hamilton from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research report on Friday, June 28th. BidaskClub lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Mizuho reaffirmed a “buy” rating and set a $77.00 target price on shares of Aerie Pharmaceuticals in a research report on Sunday, April 21st. JMP Securities set a $58.00 target price on Aerie Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Finally, Piper Jaffray Companies set a $76.00 target price on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, July 5th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. Aerie Pharmaceuticals has an average rating of “Buy” and an average target price of $71.25.

Several hedge funds have recently made changes to their positions in AERI. Fox Run Management L.L.C. purchased a new position in Aerie Pharmaceuticals during the second quarter worth approximately $276,000. Sphera Funds Management LTD. purchased a new position in Aerie Pharmaceuticals during the first quarter worth approximately $7,125,000. Marshall Wace North America L.P. lifted its position in Aerie Pharmaceuticals by 20.7% during the first quarter. Marshall Wace North America L.P. now owns 95,578 shares of the company’s stock worth $4,540,000 after buying an additional 16,405 shares in the last quarter. Granite Investment Partners LLC purchased a new position in Aerie Pharmaceuticals during the first quarter worth approximately $13,337,000. Finally, Atika Capital Management LLC purchased a new position in Aerie Pharmaceuticals during the first quarter worth approximately $3,088,000.

Shares of NASDAQ AERI traded down $0.50 during mid-day trading on Friday, reaching $23.12. 1,049,081 shares of the company were exchanged, compared to its average volume of 792,051. The company has a current ratio of 3.47, a quick ratio of 3.27 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $1.06 billion, a PE ratio of -4.97 and a beta of 0.53. Aerie Pharmaceuticals has a 1 year low of $22.45 and a 1 year high of $74.75. The business has a 50-day simple moving average of $30.20.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

See Also: Buy-Side Analysts

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.